All In Biotech

NDA 021282 · Reckitt Benckiser

Mucinex

Guaifenesin · Oral · Expectorant

Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Jul 12, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

147

31 Phase 3, 6 recruiting

FAERS reports

29,629

14,639 serious, 2,164 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 29, 2026.

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MUCINEX · GUAIFENESIN 600MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
  • MUCINEX · GUAIFENESIN 1.2GM · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Guaifenesin" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,481
  • dyspnoea2,219
  • fatigue1,810
  • nausea1,771
  • diarrhoea1,677
  • pneumonia1,671
  • cough1,601
  • headache1,535
  • dizziness1,415
  • pain1,260
  • off label use993
  • vomiting953

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004164
2005231
2006291
2007277
2008336
2009400
2010683
2011681
2012826
2013765
2014912
20152,136
20163,169
20172,376
20182,134
20192,119
20202,281
20211,420
20221,700
20231,801
20241,863
20252,159
2026902

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 60 on PubMed

Sponsor: Reckitt Benckiser

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.